CytomX Therapeutics Inc (NASDAQ:CTMX) Receives $21.61 Consensus Target Price from Analysts

Shares of CytomX Therapeutics Inc (NASDAQ:CTMX) have received an average rating of “Buy” from the fourteen research firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $20.91.

A number of equities analysts recently commented on the company. ValuEngine upgraded CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, April 1st. BidaskClub upgraded CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 7th. Nomura dropped their price objective on CytomX Therapeutics to $22.00 in a report on Monday, May 13th. Cantor Fitzgerald assumed coverage on CytomX Therapeutics in a report on Monday, May 13th. They issued an “overweight” rating and a $21.00 price objective on the stock. Finally, Mizuho assumed coverage on CytomX Therapeutics in a report on Wednesday. They issued a “buy” rating and a $16.00 price objective on the stock.

Shares of CTMX opened at $10.40 on Tuesday. CytomX Therapeutics has a fifty-two week low of $8.94 and a fifty-two week high of $27.20. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.21 and a quick ratio of 4.21.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.22. The company had revenue of $29.49 million for the quarter, compared to the consensus estimate of $13.59 million. CytomX Therapeutics had a negative return on equity of 73.62% and a negative net margin of 111.27%. As a group, equities analysts predict that CytomX Therapeutics will post -2.13 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. Citigroup Inc. increased its holdings in CytomX Therapeutics by 292.0% in the fourth quarter. Citigroup Inc. now owns 130,508 shares of the biotechnology company’s stock worth $1,971,000 after buying an additional 97,215 shares during the last quarter. Pictet Asset Management Ltd. boosted its position in CytomX Therapeutics by 0.9% during the first quarter. Pictet Asset Management Ltd. now owns 611,356 shares of the biotechnology company’s stock worth $6,572,000 after purchasing an additional 5,670 shares during the period. Exane Asset Management boosted its position in CytomX Therapeutics by 79.2% during the fourth quarter. Exane Asset Management now owns 50,000 shares of the biotechnology company’s stock worth $755,000 after purchasing an additional 22,100 shares during the period. Victory Capital Management Inc. boosted its position in CytomX Therapeutics by 3.3% during the fourth quarter. Victory Capital Management Inc. now owns 920,210 shares of the biotechnology company’s stock worth $13,895,000 after purchasing an additional 29,810 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in CytomX Therapeutics by 12.4% during the third quarter. Bank of New York Mellon Corp now owns 174,545 shares of the biotechnology company’s stock worth $3,229,000 after purchasing an additional 19,304 shares during the period. Hedge funds and other institutional investors own 81.83% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Read More: Elliott Wave Theory

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.